STAAR Surgical (Nasdaq: STAA) reported earnings on Oct. 31. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Sep. 28 (Q3), STAAR Surgical missed estimates on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue grew and GAAP earnings per share was unchanged.

Gross margins increased, operating margins shrank, net margins shrank.

Revenue details
STAAR Surgical logged revenue of $15.9 million. The six analysts polled by S&P Capital IQ anticipated a top line of $16.9 million on the same basis. GAAP reported sales were 3.9% higher than the prior-year quarter's $15.3 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.04. The two earnings estimates compiled by S&P Capital IQ averaged $0.03 per share. GAAP EPS of $0.00 were the same as the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 70.4%, 190 basis points better than the prior-year quarter. Operating margin was -0.6%, 540 basis points worse than the prior-year quarter. Net margin was -0.6%, 110 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $18.8 million. On the bottom line, the average EPS estimate is $0.04.

Next year's average estimate for revenue is $67.2 million. The average EPS estimate is $0.08.

Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 90 members out of 99 rating the stock outperform, and nine members rating it underperform. Among 25 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 20 give STAAR Surgical a green thumbs-up, and five give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on STAAR Surgical is buy, with an average price target of $9.65.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.